{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-009380","form_type":"8-K","ticker":null,"cik":"0001460602","company_name":"Orgenesis Inc.","filed_at":"2025-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.694622+00:00","generated_at":"2026-05-25T05:49:07.694174+00:00","sec_items":["1.01","2.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Orgenesis acquires spinal cord injury IP assets from Neurocords for 1.2M shares","bullets":["Acquired IP assets for advanced regenerative therapies for spinal cord injuries from Neurocords, LLC.","Issued 1,200,000 shares of common stock as consideration; shares restricted for 6 months then free-trading.","Transaction closed March 3, 2025; prior licensing agreements terminated and mutual releases executed.","Orgenesis also gets a 3-month option to acquire Rice University option agreement at no additional cost."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-009380","json":"https://secwatch.observer/filing/0001493152-25-009380.json","markdown":"https://secwatch.observer/filing/0001493152-25-009380.md","text":"https://secwatch.observer/filing/0001493152-25-009380.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1460602/000149315225009380/0001493152-25-009380-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1460602/000149315225009380/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T05:49:07.694174+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e8d1ae3d0bfc81e65a17c86c1c1c3b606cfaa38","claim":"Orgenesis Inc. completed an acquisition involving Neurocords, LLC. for 1,200,000 (one million and two hundred thousand) shares of common stock of Orgenesis.","evidence_excerpt":"Asset Purchase Agreement, in consideration for the purchase of the Assets, the Company will issue to Neurocords or any other person or entity designated in writing by Neurocords 1,200,000 (one million and two hundred thousand) shares of common stock of Orgenesis, free and clear of any trading restrictions after the initial 6-month restricted period, or any other","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1460602/000149315225009380/0001493152-25-009380-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Neurocords, LLC."},{"label":"Consideration","value":"1,200,000 (one million and two hundred thousand) shares of common stock of Orgenesis"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}